Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensified versus standard Myfortic dosing in combination immunosuppression for de novo renal transplant recipients
2005-006138-14Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mycophenolate sodium in end-stage kidney disease (ESKD) (2 arms), sponsored by Novartis. Primary endpoint: MPA exposure. Started Mar 2006; status: completed.
02
Drugs
mycophenolate sodium
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2005-006138-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-006138-14.